Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraperitoneal taxanes.

Faheez Mohamed1, Paul H Sugarbaker

  • 1Washington Cancer Institute, Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA.

Surgical Oncology Clinics of North America
|October 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morphology and Pathophysiology of 10 Different Types of Peritoneal Metastases.

Journal of surgical oncology·2026
Same author

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be safely combined with nephrectomy in patients with appendiceal malignancy and synchronous renal cell carcinoma.

Journal of surgical case reports·2026
Same author

Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years.

Journal of surgical oncology·2026
Same author

Response to Letter Comments on Raised Serum Tumor Markers Predict Incomplete Cytoreduction, Disease-Free and Overall Survival in Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and HIPEC.

Annals of surgical oncology·2026
Same author

ASO Visual Abstract: MORPHology and Inter-Observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS-The MORPHEUS Study.

Annals of surgical oncology·2026
Same author

Correction: MORPHology and Inter-observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS: The MORPHEUS study.

Annals of surgical oncology·2026

Intraperitoneal taxanes show promise for cancer treatment. Paclitaxel is in Phase III trials for ovarian cancer, while docetaxel warrants further study for peritoneal malignancies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Taxanes are a class of chemotherapy drugs.
  • Intraperitoneal chemotherapy involves delivering drugs directly into the abdominal cavity.

Purpose of the Study:

  • To evaluate the potential of taxanes for intraperitoneal administration.
  • To assess paclitaxel's efficacy in ovarian cancer and docetaxel's potential in peritoneal malignancies.

Main Methods:

  • Phase III investigation of paclitaxel for ovarian cancer.
  • Phase II study of docetaxel for peritoneal surface malignancy.

Main Results:

  • Paclitaxel is currently in advanced clinical trials for ovarian cancer.
  • Docetaxel shows potential for optimization via intraperitoneal administration for peritoneal malignancies.

Related Experiment Videos

Conclusions:

  • Intraperitoneal taxane therapy presents a promising treatment strategy.
  • Further investigation is warranted for docetaxel in peritoneal surface malignancies.